Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Adding a chatbot to specialist care helped young people make sense of cancer risk

12

Oct 2026

Adding a chatbot to specialist care helped young people make sense of cancer risk

In a randomized trial of 106 adolescents and young adults with hereditary cancer predisposition, adding AYA-RISE to a clinic visit improved knowledge of cancer risk before age 30 compared with a clinic visit alone. Researchers observed no increase in distress, but the main analyses did not establish additional benefits for lifetime-risk or screening knowledge.

AI helps neurologists distinguish epilepsy from functional seizures

12

Oct 2026

AI helps neurologists distinguish epilepsy from functional seizures

Researchers developed EpiScreen, an AI system that distinguished epilepsy from psychogenic non-epileptic seizures using clinical notes from 13,633 patient records across two institutions. AI assistance improved neurologists’ classification accuracy in a retrospective assessment of 300 cases, but prospective studies must establish its performance and benefits in routine clinical care.

Diet drinks showed no clear weight-loss edge over water after two years

11

Oct 2026

Diet drinks showed no clear weight-loss edge over water after two years

In a two-year randomized trial combining assisted weight management with an unassisted follow-up year, completers maintained average weight losses of 4.8 kg with diet drinks and 3.7 kg with water. Researchers found no significant difference between groups, but fewer than half of the 493 participants completed follow-up.

LSD microdosing linked to improved attention in women but not men

11

Oct 2026

LSD microdosing linked to improved attention in women but not men

A pilot study suggests that low doses of LSD may have different effects on sustained attention in women and men. The findings, presented at the ECNP annual congress in Munich, are preliminary, but they add to growing evidence that people may not all respond to psychedelic microdosing in the same way.

Stopping GLP-1 drugs often brings weight back. A small trial suggests ways to slow it

11

Oct 2026

Stopping GLP-1 drugs often brings weight back. A small trial suggests ways to slow it

In a randomized pilot trial of 39 adults, researchers found that participants receiving medically tailored meals or Noom regained about 3.6% of their body weight over four months after stopping GLP-1 therapy, compared with about 11% under usual care. These exploratory findings suggest structured support may slow early weight regain, but the small sample and short follow-up leave lasting benefits uncertain.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.